Gilead Sciences (NASDAQ:GILD), Novartis (NYSE:NVS)

Pablo Tucker
March 24, 2017

Hourglass Limited stated it has 1.92% in Gilead Sciences, Inc. (NASDAQ:GILD) rallied by 1.28% during the past week but lost 1.13% on a 4-week basis. The analysts believe that the company stock price could grow as high as $95.

Among 25 analysts covering Gilead Sciences (NASDAQ:GILD), 16 have Buy rating, 0 Sell and 9 Hold.

Civista Bancshares Inc (CIVB) formed double top with $23.67 target or 7.00% above today's $22.12 share price. Gilead Sciences has $137 highest and $87 lowest target. Sometimes it may seem like it, but analysts don't just pull their price targets out of thin air.

Insider Trades for Gilead Sciences Inc. show that the latest trade was made on 28 Feb 2017 where Martin (John C), the Officer and Director completed a transaction type "Sell" in which 73333 shares were traded at a price of $70.38. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences has an average rating of Buy and an average price target of $83.19.


The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements.

The current consensus rating on Gilead Sciences (NASDAQ:GILD) is Buy (Score: 2.65) with a consensus target price of $82.91 per share, a potential 22.39% upside.

Analysts are also projecting an Average Revenue Estimate for Gilead Sciences Inc.as $6.58 Billion in the Current Quarter. NASDAQ is measured to be -0.35% in conjunction with the 200-Day Simple Moving Average of -9.04%. Comparatively, Gilead Sciences Inc. posted earnings of $3 per share in the same quarter previous year. Well, according to what we could find, analysts had been looking for the company to post net income of about $2.61 per share on $7,148.62M in revenue. The business's revenue was down 13.9% on a year-over-year basis.

Annual earnings per share (EPS) growth noted at 41.20% in past 5 Years and Long-term annual earnings per share (EPS) growth is expected to reach -4.81% in coming 5 years.


Struggling to find a way in profitable zone, the current EPS estimate trend for the next year first quarter was $2.12 while three months ago that trend was for $2.13. For the next 5 years, Gilead Sciences Inc.is expecting Growth of -4.81% per annum, whereas in the past 5 years the growth was 65.8% per annum. Sandler O'Neill upgraded Civista Bancshares Inc (NASDAQ:CIVB) on Monday, October 24 to "Buy" rating. If you are accessing this piece on another site, it was illegally stolen and republished in violation of USA & global copyright and trademark law. Barclays PLC reiterated an "outperform" rating and set a $90.00 price target on shares of Gilead Sciences in a research report on Saturday, March 11th.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. CIVB's profit will be $3.28 million for 16.26 P/E if the $0.34 EPS becomes a reality. The ex-dividend date of this dividend is Tuesday, March 14th. This represents a $2.08 annualized dividend and a dividend yield of 3.07%. Gilead Sciences had 62 analyst reports since July 29, 2015 according to SRatingsIntel. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the transaction, the insider now directly owns 3,204,433 shares of the company's stock, valued at approximately $235,814,224.47. It worsened, as 106 investors sold GILD shares while 656 reduced holdings. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company's stock worth $102,000 after buying an additional 774 shares in the last quarter. Sullivan Bruyette Speros & Blaney LLC raised its stake in Gilead Sciences by 0.6% in the fourth quarter. (NASDAQ:GILD). California Public Employees Retirement invested in 3.32M shares or 0.4% of the stock. Lombard Odier Transatlantic Limited Partnership raised its position in shares of Gilead Sciences by 55.6% in the third quarter. Cable Hill Partners LLC increased its stake in Gilead Sciences by 19.1% in the third quarter. However, the company's most recent quarter decrease of 0% looks unattractive. Finally, Brown Brothers Harriman & Co. boosted its position in Gilead Sciences by 0.9% in the third quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER